NKARTA THERAPEUTICS
Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies. While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited to a few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases an... d pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile.
NKARTA THERAPEUTICS
Industry:
Biotechnology Health Care
Founded:
2015-01-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.nkartatx.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
125 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Google Tag Manager Content Delivery Network Google Universal Analytics Apache
Similar Organizations
Entrada Therapeutics
Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Obsidian Therapeutics
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
SR One
SR One investment in Series B - Nkarta Therapeutics
Amgen Ventures
Amgen Ventures investment in Series B - Nkarta Therapeutics
Deerfield
Deerfield investment in Series B - Nkarta Therapeutics
Life Sciences Partners
Life Sciences Partners investment in Series B - Nkarta Therapeutics
New Enterprise Associates
New Enterprise Associates investment in Series B - Nkarta Therapeutics
Novo Holdings
Novo Holdings investment in Series B - Nkarta Therapeutics
Samsara BioCapital
Samsara BioCapital investment in Series B - Nkarta Therapeutics
Logos Capital
Logos Capital investment in Series B - Nkarta Therapeutics
RA Capital Management
RA Capital Management investment in Series B - Nkarta Therapeutics
New Enterprise Associates
New Enterprise Associates investment in Series A - Nkarta Therapeutics
Official Site Inspections
http://www.nkartatx.com Semrush global rank: 2.42 M Semrush visits lastest month: 7.47 K
- Host name: 238.41.180.107.host.secureserver.net
- IP address: 107.180.41.238
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Nkarta Therapeutics"
Natural Killer Cells (NK Cells) for the treatment of cancers and ...
We are dedicated to realizing the potential of natural killer (NK) cells for the treatment of cancer. Our proprietary technology is designed to harness the power of these important pathogen …See details»
The Management, Board of Directors and Scientific Advisory Board …
Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated …See details»
The Management, Board of Directors and Scientific Advisory Board …
About nkarta. Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with life …See details»
Nkarta, Inc. - LinkedIn
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic natural killer (NK) cell therapies.See details»
Corporate Governance - Nkarta, Inc.
The Board of Directors of Nkarta, Inc. (the "Company") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of sound …See details»
Nkarta Therapeutics - Crunchbase Company Profile & Funding
Nkarta Therapeutics is a developer of cell engineering platform created to build the next generation of cell therapies. View contacts for Nkarta Therapeutics to access new leads and …See details»
Contact information for Nkarta Inc.
We're based in South San Francisco and are scientific leaders in mastering NK cells – one of the body's most powerful responders against disease and pathogens – to develop breakthrough …See details»
Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results …
Dec 31, 2023 · SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing …See details»
Nkarta - EQT Group
Nov 18, 2024 · nkartatx.com. Sector. Healthcare. Country. United States. Fund. LSP 6. Entry. 2019. Web. nkartatx.com. Latest news. 22 November 2024 EQT Exeter To Acquire More Than …See details»
Careers and Job Opportunities at Nkarta Inc. - nkartatx.com
We are a young, innovative company with an intense purpose and passion for bringing innovation to patients with cancer. Join us and work with some of the brightest, most dedicated people in …See details»
Nkarta Reports Second Quarter 2022 Financial Results and …
SOUTH SAN FRANCISCO, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) …See details»
Nkarta, Inc. (NKTX) Company Profile & Overview - Stock Analysis
Jul 10, 2020 · Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment.See details»
Nkarta to Participate in an Upcoming Investor Conference
2 days ago · A simultaneous webcast of the event will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for …See details»
Nkarta - Overview, News & Similar companies | ZoomInfo.com
Nkarta contact info: Phone number: (415) 582-4923 Website: www.nkartatx.com What does Nkarta do? Nkarta is a clinical-stage biotechnology company advancing the development of …See details»
Nkarta Launches Trial for CAR-NK Therapy NKX019 in Lupus
Jul 9, 2024 · The clearance of our second IND in autoimmune disease broadens the development of NKX019 and enables us to evaluate 3 additional B-cell mediated diseases in parallel. We …See details»
Nkarta Therapeutics Appoints Two New Independent Directors
SOUTH SAN FRANCISCO, Calif. – April 27, 2020 – Nkarta, Inc. (Nkarta), a privately-held biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat …See details»
NK Cells | Natural Killer Cells for the treatment of cancers and ...
Nkarta’s proprietary NK cell therapy platform is designed to maximize the therapeutic effect of allogeneic NK cells through robust expansion, enhanced targeting and extended persistence …See details»
Nkarta Announces Updated Clinical Data on Anti-CD19 Allogeneic …
Dec 5, 2022 · SOUTH SAN FRANCISCO, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer cell …See details»
NKTX Stock Price & Charts | Nkarta
Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer and autoimmune diseases. The Company is engaged in leveraging the …See details»
Publications for Nkarta Inc. - nkartatx.com
News & Publications for Nkarta Inc., Nkarta is developing proprietary methods of boosting the immune response through allogeneic, off-the-shelf NK cell-based therapies.See details»